Novartis Ag (NVSEF) Accounts Payables (2009 - 2025)

Novartis Ag has disclosed Accounts Payables across 14 years of filings, most recently posting $4.5 billion for Q4 2025.

• Accounts Payables for Q4 2025 came in at $4.5 billion, down 2.54% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.5 billion (down 2.54% YoY), and the FY2025 annual result was $4.5 billion, down 2.54% from the prior year.
• Accounts Payables came in at $4.5 billion for Q4 2025 at Novartis Ag, down from $4.5 billion in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $5.6 billion in Q4 2021 to a low of $4.1 billion in Q2 2024.
• The 5-year median for Accounts Payables is $4.9 billion (2021), against an average of $4.8 billion.
• Across the five-year window, Accounts Payables dropped 22.5% in 2024 and advanced 8.68% in 2025, its largest moves.
• Novartis Ag's Accounts Payables stood at $5.6 billion in 2021, then dropped by 7.33% to $5.1 billion in 2022, then declined by 4.28% to $4.9 billion in 2023, then fell by 7.19% to $4.6 billion in 2024, then dropped by 2.54% to $4.5 billion in 2025.
• The last three Accounts Payables figures came in at $4.5 billion (Q4 2025), $4.5 billion (Q2 2025), and $4.6 billion (Q4 2024), per Business Quant data.